Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Severe acute respiratory syndrome coronavirus type 1 (SARS-C...

Class:IdSummation:9685156
_displayNameSevere acute respiratory syndrome coronavirus type 1 (SARS-C...
_timestamp2021-02-19 19:27:17
created[InstanceEdit:9685159] Shamovsky, Veronica, 2020-04-22
literatureReference[LiteratureReference:9685164] Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex
[LiteratureReference:9685165] Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain
modified[InstanceEdit:9693607] Shamovsky, Veronica, 2020-07-03
[InstanceEdit:9711067] Shamovsky, Veronica, 2021-01-11
[InstanceEdit:9713615] Shamovsky, Veronica, 2021-01-27
[InstanceEdit:9716144] Shamovsky, Veronica, 2021-02-19
textSevere acute respiratory syndrome coronavirus type 1 (SARS-CoV-1) M protein is a glycosylated structural protein with three transmembrane (TM) domains. M protein predominantly localizes to the Golgi complex and is essential for the assembly of viral particles. SARS-CoV-1 M protein was found to suppress production of type I IFNs in human embryonic kidney 293 cells (HEK293 cells) expressing RIG-I (DDX58), MDA5 (IFIH1), TRAF3, TBK1 and IKKε (IKBKE) proteins (Siu KL et al. 2009; 2014). IFN antagonism was mediated by N-terminal TM1 domain of SARS-CoV-1 M protein (amino acids 1–38), which targets M protein to the Golgi complex (Siu KL et al. 2014). Co-immunoprecipitation analysis revealed that TM1 of M protein interacted with TRAF3, RIG-I (DDX58), TBK1 and IKBKE (Siu KL et al. 2014) in HEK293 expressing tagged proteins (Siu KL et al. 2014). SARS-CoV-1 M protein is thought to prevent the formation of the TRAF3:TANK:TBK1/IKBKE complex and thereby inhibits TBK1/IKBKE-dependent activation of IRF3/IRF7 transcription factors (Siu KL et al. 2009; 2014). The Reactome event shows binding of SARS-CoV-1 M protein to TRAF3. This binding prevents TRAF3 from interacting with downstream effectors TANK, TBK1 and IKBKE (IKKε). However, it remains to be clarified how the Golgi-associated M protein might contribute to the suppression of IRF3/IRF7 activation under the DDX58:MAVS antiviral signaling axis.
(summation)[Reaction:9685162] SARS-CoV-1 M protein interacts with TRAF3 [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Severe acute respiratory syndrome coronavirus type 1 (SARS-C... (9685156)
Follow Reactome